OncoMatch/Clinical Trials/NCT05549024
68Ga-RM26-RGD PET/CT Imaging in the GRPR and αvβ3 Positive Tumor Patients
Is NCT05549024 recruiting? Yes, currently enrolling (Jun 2026). This Early Phase 1 trial studies multiple treatments including 68Ga-RM26-RGD and 18F-FDG for breast cancer.
Treatment: 68Ga-RM26-RGD · 18F-FDG · 68Ga-RM26 · 68Ga-RGD — Based on the high expression of specific receptors on the surface of diseased tissues and neovascularization, noninvasive targeted molecular imaging can be used to visualize lesions in vitro by combining specific ligands labeled with short half-life isotopes. In this study, a novel dual-target imaging agent 68Ga-RM26-RGD was used for clinical study of tumor PET/CT imaging to further verify its clinical application value.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Breast Carcinoma
Prostate Cancer
Glioblastoma
Biomarker criteria
Required: GRPR positive
GRPR and αvβ3 Positive Tumor Patients
Required: ITGAV positive
GRPR and αvβ3 Positive Tumor Patients
Required: ITGB3 positive
GRPR and αvβ3 Positive Tumor Patients
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05549024 currently recruiting?
Yes, this trial is currently recruiting patients.
Does this trial require GRPR?
Yes, GRPR positive is a required biomarker for enrollment.
Does this trial require ITGAV?
Yes, ITGAV positive is a required biomarker for enrollment.
Does this trial require ITGB3?
Yes, ITGB3 positive is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages